Who should consider a donor (allo) transplant? Young, high-risk myeloma patients and patients with high relapse risk. Considering clinical trials as your first treatment option with Dr. Parmeswaran Hari.

Shutting down myeloma growth by changing the soil where it grows with Dr. Noopur Raje of Massachusetts General Hospital Cancer Center

What can you do when your myeloma medication is no longer working? Dr. Jatin Shah describes the best new approaches to overcome drug resistance and a host of treatment alternatives.

Are you confused by your myeloma labs? Dr. Michael Misialek says your pathologist is ready and willing to help decipher the results.

The path to personalized medicine: Dr. Gareth Morgan describes his work to subdivide myeloma into actionable types, target specific genes and pathways, and study the impact of the bone marrow environment

Dr. Rodger Tiedemann discusses why myeloma persistently returns and his work to strike at the root of the disease by targeting earlier stage progenitor cells

Dr. Rafael Fonseca of the Mayo Clinic Scottsdale discusses today's and tomorrow's myeloma genetic approaches

Dr. Frits van Rhee of UAMS discusses Total Therapy, his approach to address high-risk patient needs, and the importance genetic and imaging tests and how these pinpoint prognosis and best treatment path options

Dr. Shaji Kumar of the Mayo Clinic discusses the road to personalized myeloma treatment and three approaches we can take today before targeted treatments become a clinic reality